ETNB - 89bio aligns with regulators on Phase 3 trials for NASH candidate
2023-12-04 10:54:59 ET
More on 89bio
- 89bio's Low Price Presents An Opportunity
- 89bio: Risk And Reward Balance In NASH Therapeutics
- 89bio gains FDA breakthrough status for NASH candidate
- Seeking Alpha’s Quant Rating on 89bio
- Historical earnings data for 89bio
For further details see:
89bio aligns with regulators on Phase 3 trials for NASH candidate